Related Experiment Video

Updated: Jan 5, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives

H Taghizadeh1,2, M Marhold1,2, E Tomasich1,2

  • 1Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.

Oncoimmunology
|October 25, 2019
PubMed

Insights

Immune checkpoint inhibitors show promise in cancer but have disappointed in metastatic castration-resistant prostate cancer (mCRPC) trials. This review examines current mCRPC immunotherapy strategies and future directions.

Area of Science:

  • Oncology
  • Immunology
  • Clinical Trials

Background:

  • Immune-therapeutics demonstrate efficacy in various cancers.
  • Castration-resistant prostate cancer (mCRPC) has seen disappointing Phase III trial results for immune-therapeutics.

Purpose of the Study:

  • To systematically review immune checkpoint inhibitors in mCRPC.
  • To understand the role and application of immune-therapeutics in mCRPC.
  • To identify strategies for future clinical success.

Main Methods:

  • Systematic literature search of ClinicalTrials.gov, PubMed, and ASCO Meeting Library.
  • Focused on clinical trials involving immune checkpoint inhibitors for mCRPC.

Main Results:

  • Summarizes the current landscape of immune checkpoint inhibitor trials in mCRPC.
  • Details the rationale behind individual clinical trials.
  • Identifies trends and challenges in mCRPC immunotherapy.

Conclusions:

  • Despite setbacks, immune checkpoint inhibitors remain an area of research interest for mCRPC.
  • Further investigation into trial rationale and future strategies is crucial.
  • Optimizing immunotherapy approaches is key for improving outcomes in mCRPC.
Keywords:
T lymphocytescheckpoint inhibitorsimmunotherapymCRPCvaccines

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K